Unisphere Establishment Increases Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Unisphere Establishment grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,700,000 shares of the medical research company’s stock after purchasing an additional 100,000 shares during the quarter. Thermo Fisher Scientific comprises approximately 7.7% of Unisphere Establishment’s holdings, making the stock its 3rd largest holding. Unisphere Establishment owned 0.44% of Thermo Fisher Scientific worth $884,391,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Navigoe LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $37,000. Connors Investor Services Inc. boosted its position in Thermo Fisher Scientific by 3.6% during the 4th quarter. Connors Investor Services Inc. now owns 19,194 shares of the medical research company’s stock worth $9,985,000 after acquiring an additional 665 shares during the last quarter. Evergreen Wealth Solutions LLC boosted its position in Thermo Fisher Scientific by 6.1% during the 4th quarter. Evergreen Wealth Solutions LLC now owns 2,078 shares of the medical research company’s stock worth $1,081,000 after acquiring an additional 120 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 8,422.4% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 31,192 shares of the medical research company’s stock worth $16,227,000 after purchasing an additional 30,826 shares in the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 4.6% during the 4th quarter. AQR Capital Management LLC now owns 221,202 shares of the medical research company’s stock worth $115,076,000 after purchasing an additional 9,797 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares of the company’s stock, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock valued at $13,106,062 over the last ninety days. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Up 1.5 %

TMO opened at $427.56 on Wednesday. Thermo Fisher Scientific Inc. has a twelve month low of $409.85 and a twelve month high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The company has a fifty day moving average of $482.87 and a 200-day moving average of $524.80. The stock has a market cap of $161.40 billion, a PE ratio of 25.87, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Thermo Fisher Scientific’s revenue was up .2% on a year-over-year basis. During the same period in the prior year, the firm earned $5.11 earnings per share. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were given a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.09%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. UBS Group dropped their price objective on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Stifel Nicolaus dropped their price target on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Robert W. Baird dropped their price target on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th. Evercore ISI lowered their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Finally, Raymond James reiterated an “outperform” rating and set a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $610.27.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.